HIGHLIGHTS
SUMMARY
Severe asthma accounts for no more than 2% of all cases of bronchial asthma in the pediatric population and most exacerbations are seen in patients with mild and moderate forms of asthma. Both Global Initiative for Asthma (GINA) and the National Asthma Education and Prevention Program Coordinating Committee (NAEPP) recommend the use of a single inhaler containing the combination of an inhaled corticosteroid (ICS) and formoterol, a specific fast-acting bronchodilator (FABA), for both maintenance and quick relief therapy in steps 3 and 4 of asthma management. Children with asthma must be evaluated for . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.